摘要
目的通过分析BRAF V600E蛋白在甲状腺乳头状癌(papillary thyroid carcinoma,PTC)合并桥本甲状腺炎(Hashimoto’s thyroiditis,HT)中的表达情况,探讨其表达的临床病理意义。方法选取2017年1月~2019年7月间行手术治疗且行中央淋巴结清扫的465例经典型PTC为研究对象,将其分为PTC合并HT组(139/465)和单纯PTC组(326/465),用免疫组化EnVision法检测两组中BRAF V600E蛋白表达情况,并对检测结果及临床病理特征进行统计学分析。结果PTC合并HT组中BRAF V600E蛋白的阳性率(59.71%)低于单纯PTC组(69.94%),差异有统计学意义(P=0.032);PTC合并HT组中BRAF V600E蛋白阴性组患者发病年龄<55岁的比例更高(92.86%);与单纯PTC组相比,PTC合并HT组女性(88.49%)患病率明显高于男性(67.79%),差异有统计学意义(P<0.001);PTC中HT或BRAF V600E蛋白表达与肿瘤大小、肿瘤多发、中央区淋巴结转移均无关(P>0.05)。结论PTC合并HT患者BRAF V600E蛋白的阳性率较低。PTC中HT或BRAF V600E蛋白表达与肿瘤大小、肿瘤多发、中央区淋巴结转移无关。
Purpose To investigate the expression of BRAF V600E protein and to discuss the potential clinicopathological significance in papillary thyroid carcinoma(PTC)with Hashimoto’s thyroiditis(HT).Methods 465 patients who underwent thyroidectomy with central lymph node dissection and were diagnosed with classical PTC from January 2017 to July 2019 were enrolled.PTC patients were divided into two groups:PTC with HT group(139/465)and PTC without HT group(326/465).The presence of mutant BRAF V600E protein was evaluated by immunohistochemistry between the two groups.Statistical analysis was used to access the association between BRAF V600E protein expression and clinicpathological characters.Results The present study showed that the positive expression of BRAF V600E in PTC with HT group was lower than that in PTC without HT group,and had statistical significance(59.71%vs 69.94%,P=0.032).In PTC with HT group,BRAF V600E negative expression meant a higher proportion of age at diagnosis below 55 years old(92.86%).The female incidence rates were higher than male in PTC with HT group(88.49%vs 67.79%,P<0.001).HT or BRAF V600E expression in PTC had no statistical difference in tumor size,multifocality or central lymph node metastasis(P>0.05).Conclusion The positive expression rate of BRAF V600E in PTC with HT group is lower than that in PTC without HT group.HT or BRAF V600E protein expression has no significant association with tumor size,multifocality or central lymph node metastasis.
作者
马东林
朴颖实
毛美玲
曹丁方
刘红刚
MA Dong-lin;PIAO Ying-shi;MAO Mei-ling;CAO Ding-fang;LIU Hong-gang(Department of Pathology, Beijing Tongren Hospital/Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Capital Medical University, Beijing 100730, China)
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2020年第6期677-681,共5页
Chinese Journal of Clinical and Experimental Pathology
基金
北京市医管局扬帆计划(ZYLX201814)。
作者简介
马东林,女,硕士,技师,E-mail:madonglin917@163.com;通讯作者:刘红刚,男,教授,E-mail:lhg1125@163.com。
